Michael S. Ostrach Net Worth

The estimated Net Worth of Michael S Ostrach is at least $2.87 Миллион dollars as of 22 February 2020. Mr Ostrach owns over 8,500 units of Dynavax Technologies stock worth over $1,768,555 and over the last 18 years he sold DVAX stock worth over $378,989. In addition, he makes $721,353 as Advisor at Dynavax Technologies.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Ostrach DVAX stock SEC Form 4 insiders trading

Mr has made over 7 trades of the Dynavax Technologies stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 8,500 units of DVAX stock worth $92,735 on 22 February 2020.

The largest trade he's ever made was exercising 60,780 units of Dynavax Technologies stock on 1 May 2012 worth over $57,133. On average, Mr trades about 6,273 units every 95 days since 2006. As of 22 February 2020 he still owns at least 162,104 units of Dynavax Technologies stock.

You can see the complete history of Mr Ostrach stock trades at the bottom of the page.

Mr. Michael S. Ostrach biography

Michael S. Ostrach is the Advisor at Dynavax Technologies.

What is the salary of Mr Ostrach?

As the Advisor of Dynavax Technologies, the total compensation of Mr Ostrach at Dynavax Technologies is $721,353. There are 3 executives at Dynavax Technologies getting paid more, with Ryan Spencer having the highest compensation of $859,990.

How old is Mr Ostrach?

Mr Ostrach is 69, he's been the Advisor of Dynavax Technologies since . There are no older and 5 younger executives at Dynavax Technologies.

What's Mr Ostrach's mailing address?

Michael's mailing address filed with the SEC is C/O DYNAVAX TECHNOLOGIES, 2100 POWELL STREET, SUITE 900, EMERYVILLE, CA, 94608.

Insiders trading at Dynavax Technologies

Over the last 21 years, insiders at Dynavax Technologies have traded over $196,839,440 worth of Dynavax Technologies stock and bought 2,463,112 units worth $11,318,051 . The most active insiders traders include Andrew A. F. Hack, Partners L P/Ilbiotechnolog... и James Edeerfield Capital Lp.... On average, Dynavax Technologies executives and independent directors trade stock every 43 days with the average trade being worth of $1,533,390. The most recent stock trade was executed by Francis Cano on 31 May 2024, trading 3,615 units of DVAX stock currently worth $43,127.

What does Dynavax Technologies do?

dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.

Complete history of Mr Ostrach stock trades at Dynavax Technologies

Dynavax Technologies executives and stock owners

Dynavax Technologies executives and other stock owners filed with the SEC include:

• Ryan Spencer,
  CEO & Director
• David F. Novack,
  Pres & COO
• Dr. Robert Janssen,
  Chief Medical Officer and Sr. VP of Clinical Devel., Medical & Regulatory Affairs
• Michael S. Ostrach,
  Advisor
• John Slebir,
  Sr. VP & Gen. Counsel
• Nicole Arndt,
  Sr. Mang. of Investor Relations
• Meg Smith,
  VP Sales & Operations
• Steven N. Gersten,
  Chief Ethics & Compliance Officer, Sr. VP, Gen. Counsel and Sec.
• Heather Rowe,
  VP of Investor Relations & Corp. Communications
• Jeff P. Coon,
  Sr. VP of HR & Admin.
• Justin Burgess,
  Principal Accounting Officer & Controller
• Kelly MacDonald,
  Sr. VP & CFO
• Laura Brege,
  Director
• Eddie Gray,
  CEO and Director
• Arnold L Oronsky,
  Director
• Stanley A Plotkin,
  Director
• Daniel L Kisner,
  
• Dennis Carson,
  Director
• Natale S Ricciardi,
  Director
• David Louis Johnson,
  Vice President
• Michael S Ostrach,
  Senior Vice President
• Elaine D Sun,
  
• Francis Cano,
  
• Peter R. Paradiso,
  
• Peggy V Phillips,
  
• Brent Mac Gregor,
  
• Julia Marie Eastland,
  
• Scott Dunseth Myers,
  
• Partners L P/Ilbiotechnolog...,
  
• Nest Gary A Van,
  Vice President
• Dino Dina,
  President and CEO
• Denise Gilbert,
  Director
• Martin E Sanders,
  EVP, Chief Development Officer
• James Edeerfield Capital Lp...,
  
• Partners L P/Ilbiotechnolog...,
  
• James Edeerfield Capital Lp...,
  
• James Edeerfield Capital Lp...,
  
• Deborah A Smeltzer,
  VP Operations & CFO
• Timothy G Henn,
  Vice President
• Zbigniew Janowicz,
  Director
• Daniel Janney,
  Director
• Stephen F Tuck,
  Vice President
• Nancy L Buc,
  Director
• J Tyler Martin,
  VP Clinical Development & CMO
• Christine R Larson,
  VP and Chief Financial Officer
• Capital Partners Lpsymphony...,
  
• Jennifer Lew,
  VP, Finance & PAO
• Mark Kessel,
  Director
• David M Lawrence,
  Director
• Daniel J Levitt,
  VP and Chief Medical Officer
• James Edeerfield Capital Lp...,
  
• Louis C Bock,
  Director
• Jan Leschly,
  Director
• James E Flynn,
  10% owner
• Danielalta California Partn...,
  
• Robert Coffman,
  VP & Chief Scientific Officer
• David F Novack,
  President & COO
• Ryan Spencer,
  CEO and Director
• Robert Janssen,
  SVP and CMO
• Kelly Mac Donald,
  SVP and CFO
• Justin Burgess,
  VP Finance & CAO
• Andrew A. F. Hack,